Affiliation:
1. Baptist Medical Group, Collierville, Tennessee
2. The University of Tennessee Health Science Center, Memphis, Tennessee
3. Premier Prevention Memphis, Memphis, Tennessee
4. Health Promotion and Disease Prevention, The University of Tennessee Health Science Center, Memphis, Tennessee
Abstract
ABSTRACT
The complex interplay of increased atherogenic lipoproteins, inflammation, and immune activation hallmarks the pathogenesis of atherosclerotic cardiovascular disease (ASCVD). Atherosclerotic cardiovascular disease remains a leading cause of death, yet risk estimator tools lack comprehensiveness for genetic/inflammatory biomarkers associated with ASCVD. Unexplained ASCVD risk necessitates a better understanding of primary, secondary, and tertiary prevention variables. This article discusses the clinical utility of genetic and inflammatory biomarkers for ASCVD risk prediction, management, treatment, and recategorization into primary, secondary, and tertiary prevention. Furthermore, nurse practitioners (NPs) should use a ternary prevention classification system instead of the current binary system to mitigate risk in the large group of patients with subclinical ASCVD. High-sensitivity C-reactive protein (hs-CRP)—linearly associated with ASCVD—and lipoprotein-associated phospholipase-A2 (Lp-PLA2) and myeloperoxidase (MPO), both associated with plaque vulnerability/rupture, are inflammatory biomarkers. Elevated hs-CRP, MPO, and Lp-PLA2 treatment requires addressing root causes of elevation (e.g., obesity, insulin resistance, tobacco use, gingival disease, and chronic autoimmune/infectious conditions). In addition, haptoglobin (Hp) phenotype determines the antioxidant potential of Hp. Haptoglobin phenotype, a root cause of ASCVD, is a one-time test. Individuals with Hp 2-2 should adopt a gluten-free diet to reduce endothelial and intestinal inflammation. Nurse practitioners should use stricter glycemic goals (hemoglobin A1c ≤6.5%) and add daily vitamin E if this group has type 2 diabetes. Genetic/inflammatory biomarkers should be used to better predict ASCVD risk and tailor primary, secondary, and tertiary prevention treatment. Clinical use of these biomarkers reaches beyond the standard of care to reduce residual ASCVD risk.
Publisher
Ovid Technologies (Wolters Kluwer Health)
Subject
General Medicine,General Nursing
Reference26 articles.
1. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: A report of the American College of Cardiology/American heart association task force on clinical practice guidelines;Arnett;Circulation,2019
2. High-risk periodontal pathogens contribute to the pathogenesis of atherosclerosis;Bale;Postgraduate Medical Journal,2017
3. Vitamin E reduces cardiovascular disease in individuals with diabetes mellitus and the haptoglobin 2-2 genotype;Blum;Pharmacogenomics,2010
4. Prognostic value of myeloperoxidase in patients with chest pain;Brennan;New England Journal of Medicine,2003
5. Haptoglobin phenotype modifies the influence of intensive glycemic control on cardiovascular outcomes;Carew;Journal of the American College of Cardiology,2020